Nature Clinical Practice Oncology (2008) 5, 18-23
Principles and Practice of Oncology 2008 Update
J Clin Oncol. 2005 Dec 20; 23(36): 9443-4Thomas JM
Br J Surg. 2008 May; 95(5): 664; author reply 664-5Thomas JM, Hayes A
Eur J Surg Oncol. 2007 Nov 26; Clark MA, Johnson MB, Thway K, Fisher C, Thomas JM, Hayes AJ INTRODUCTION: Clear cell sarcoma (CCS) is a rare tumour with a propensity for local recurrence and nodal metastasis. About 300 cases have been reported, thus further clarification regarding the course and outcome of the disease is [...]
N Engl J Med. 2007 Jan 25; 356(4): 418; author reply 419-21Thomas JM
J Plast Reconstr Aesthet Surg. 2007; 60(1): 32-40Giblin AV, Thomas JM Cutaneous melanoma remains a challenge despite increased levels of awareness, education and targeted health policies. Worldwide incidence rates for cutaneous melanoma have risen faster than those for any other malignancy in Caucasian populations over the last 30 years. Despite improving survival rates (defined as [...]
Clin Adv Hematol Oncol. 2007 Jun; 5(6): 483-90Sondak VK, Zager JS, Messina JL, Thomas JM
Ann Surg Oncol. 2007 Jan; 14(1): 230-8Hayes AJ, Neuhaus SJ, Clark MA, Thomas JM BACKGROUND: Isolated limb perfusion (ILP) with melphalan is used in the treatment of advanced in-transit melanoma but has no real efficacy for irresectable soft tissue sarcomas arising in the extremities. The addition of tumor necrosis factor (TNF)-alpha may increase response rates [...]
ANZ J Surg. 2006 Nov; 76(11): 1038-9; author reply 1039-40Thomas JM